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Abstract
Background: The tumor suppressor gene CDC73 was found to be associated with hyperparathyroidism-jaw tumor
syndrome (HPT-JT), which is characterized by parathyroid adenoma or carcinoma, ossifying fibroma (OF) of the
jaws, and renal and uterine lesions. Mutations in CDC73 have also been frequently detected in sporadic parathyroid
carcinomas and renal tumors. However, the prevalence and range of CDC73 mutations in sporadic OFs have not
been established.
Methods: We directly sequenced coding and flanking splice junctional regions of CDC73 in 40 cases of sporadic
OF of the jaws. We also used immunohistochemistry to detect parafibromin, the protein product of CDC73, in
those cases.
Results: Two novel CDC73 mutations were identified in 2 of the 40 cases (5 %). Both were somatic mutations
located in exon 1 of the coding region. Strong parafibromin expression was detected in all 40 cases, irrespective
of the presence of CDC73 mutations.
Conclusions: Mutations inCDC73 were rare in sporadic OF of the jaws, but may affect the pathogenesis of a small
subset of tumors of this type.
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Background
According to the World Health Organization, it is pro-
posed that benign fibro-osseous lesions be divided into 3
categories, including fibrous dysplasia, ossifying fibroma,
and osseous dysplasia [1, 2]. The most common forms
of BFOL are ossifying fibroma (OF) and fibrous dysplasia
(FD) and they manifest different clinical courses and
should be treated differently [3].
Ossifying fibroma is a benign tumor thought to arise
from the periodontal ligament, which potential of con-
tinuous growth if not treated [4, 5]. It is a slow-
growing, generally lack of symptoms, but can cause
serious cosmetic and functional problems. [6] OF can
occur in almost any bone in the craniofacial region,
predominantly in the premolar-molar region of the
mandible, with adult women more frequently affected
[7]. Radio-graphically, OF usually presents a well-
circumscribed radiolucency with varying degrees of
calcification that rarely erodes or displaces teeth [4].
Ossifying fibromas are typically encountered as soli-
tary lesions, multiple and/or familial lesions rarely
present in clinic [8]. In some instances, OF can be
destructive and risk for recurrence, as a result of
which completely surgical enucleating is needed [9].
FDs are genetic and non-inheritable, caused by mis-
sense mutations that occur post-zygotically in the gene,
GNAS, which is located on chromosome 20q13 and
codes for the a-subunit of the stimulatory G-protein, Gs
[10]. The mutations generate a somatic mosaic and the
resulting proteins display reduced GTPase activity and,
consequently, increased activation of adenylyl cyclase.
Therefore, mutated cells constitutively generate high
levels of cAMP and have a high rate of proliferation
[11]. The differential diagnostic value of GNAS in FD is
well recognized. In previous studies, our research group
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demonstrated that, in a total of 307 cases of FD and 23
cases of OF, the mutation rate of GNAS in patients with
FD was approximately 86 % (264/307), while GNAS
mutations were not found in patients with OF. [12]
Little is known about the etiology of OF.
Hyperparathyroidism-jaw tumor (HPT-JT) syndrome
is an autosomal dominant, multiple neoplasia syndrome
which is characterized by parathyroid adenoma or car-
cinoma, ossifying fibroma of the jaws, renal and uterine
lesions [13, 14]. Between 30 and 40 % of individuals with
HPT-JT also develop OFs, which are distinct from the
“brown” tumors associated with severe hyperparathyr-
oidism.. The HPT-JT locus was mapped to chromosome
1q24–q32; the putative gene, designated first as hyper-
parathyroidism type 2 (HRPT2) and then as CDC73,
encodes a 531 amino acid protein called parafibromin.
[15] Parafibromin is ubiquitously expressed and is evolu-
tionarily conserved. It is the human homologue of yeast
Cdc73, which is a component of the yeast RNA poly-
merase II/Paf1 complex that is important for histone
modification and post-transcriptional events [16, 17].
Mutations in CDC73 can be detected in approximately
58 % of probands with clinical features of HPT-JT
syndrome [15]. In one series, which included four cases
with OFs, mutations in CDC73 were found in two of the
cases [18].
Collectively, these data suggested that CDC73 may be
a key factor in the etiology of HPT–JT syndrome and its
related tumors, including OFs. The prevalence and range
of CDC73 mutations in sporadic OFs remain to be
determined, in view of the limited number of cases
examined to date. The goal of the present study was
to identify CDC73 mutations in a group of Chinese
patients presenting with sporadic OFs and to examine




The fresh tumor specimens and peripheral blood sam-
ples of 40 sporadic OFs were obtained from the Depart-
ment of Oral Pathology, Peking University Hospital and
School of Stomatology, during 2003–2015. The diagnosis
was made according to the WHO classification of odon-
togenic tumors [2]. Samples were only collected if the
patient’s family history was negative and PTH serum
level was normal, to exclude cases of HPT-JT related
OF. Detailed information regarding these cases is pro-
vided in Table 1.
DNA Extraction and Polymerase Chain Reaction (PCR)
Genomic DNA was extracted from frozen samples
(25 mg) of neoplastic tissue and peripheral blood by
using a DNeasy Tissue Kit (Qiagen Sciences, Maryland,
USA). The 17 coding exons of CDC73 were amplified as
15 different fragments with primers derived from the
flanking intronic or 3′/5′UTR regions, to allow the de-
tection of mutations that occurred in coding regions or
that affected splicing, as previously described [19]. The
condition of PCR was used as follows: initial denatur-
ation at 95°C for 5 min; 35 cycles of denaturation at 95 °
C for 30 s, annealing at 58–62 °C for 30 s, elongation at
72 °C for 30 s; and a final extension at 72 °C for 7 min.
Direct sequencing
The amplified PCR products were gel-purified and dir-
ectly sequenced. When nucleotides insertion or deletion
was detected, clone sequencing by the plasmid vector
was used for confirmation. The method of clone sequen-
cing were carried out by previously described [20]. All
detected mutations were confirmed by reverse sequen-
cing and at least two independent experiments.
Immunohistochemistry
Parafibromin expression was evaluated in formalin-fixed
and paraffin-embedded tissues by immunohistochemical
staining as previously described [21], using a mouse
monoclonal anti-parafibromin antibody (SC-33638, Santa
Cruz Biotechnology Inc., Santa, Cruz, CA, USA) that rec-
ognizes amino acids 87–100.
Results
Clinicopathological features
The clinical characteristics of the 40 cases enrolled in
this study are summarized in Table 1. The patient age at
first presentation ranged from 1 to 47 years (median age:
19.5 years). The male to female ratio was 19:21. Seven-
teen (44.7 %, 17/38) tumors occurred in the maxilla,
while 21 (55.3 %, 21/38) occurred in the mandible. Two
cases, which have been reported previously [8], showed
multiple lesions affecting both the maxilla and the man-
dible. Bone or facial swelling (90 %, 36/40) was the most
common clinical presentation, and other presentations
included pain (10 %, 4/40), bite pain (2.5 %, 1/40), nasal
obstruction (5 %, 2/40), sense of numbness (7.5 %, 3/40),
sense of discomfort (5 %, 2/40), looseness of teeth
(2.5 %, 1/40), tinnitus (2.5 %, 1/40), and surface fester
(2.5 %, 1/40). In 38 of 40 patients with available ra-
diographs, radiographic features included radiolucent
(eight cases, 21 %), mixed (25 cases, 66 %;), and
radioopaque lesions (5 cases, 13 %). Lesions of 29
cases were well-defined, and those of 9 cases were
ill-defined.
CDC73 mutations
Results from the mutational analysis of CDC73 in 40 cases
of OF are summarized in Table 1. Two novel CDC73 mu-
tations were identified in two cases. Both mutations were
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Table 1 Clinical data and CDC73 mutation of 40 patients with sporadic ossifying fibromas
Patient Age (y) Gender Location Symptoms and signs Radiographic findings CDC73 mutation
1 10 female right maxilla right facial swelling
bite pain
Mixed lesion well demarcated c.13-16delCTTA
2 18 female left mandible left posterior teeth
discomfort
Mixed lesion well demarcated c.8-10delACGinsCT
3 23 female left mandible bone swelling Mixed lesion ill demarcated No mutation
4 18 female right mandible right facial swelling
occasional discomfort
Mixed lesion well demarcated No mutation
5 20 female left maxilla left facial swelling
surface fester
Mixed lesion well demarcated No mutation
6 46 female left mandible bone swelling
numbness of lower lip
unavailable unavailable No mutation
7 39 female left mandible bone swelling Radiolucent well demarcated No mutation
8 1 male right mandible right facial swelling unavailable unavailable No mutation
9 14 male left mandible bone swelling Radio-opaque well demarcated No mutation
10 34 male left mandible left facial swelling Radio-opaque well demarcated No mutation
11 10 male left maxilla right facial swelling
tinnitus
Radiolucent well demarcated No mutation
12 43 female anterior maxillary
region
bone swelling Radio-opaque well demarcated No mutation
13 15 male left mandible bone swelling Mixed lesion well demarcated No mutation
14 22 female left maxilla bone swelling Radio-opaque well demarcated No mutation
15 31 female right mandible buccal and lingual bone
expansion
mildly pain
Mixed lesion well demarcated No mutation
16 32 female left mandible buccal and lingual bone
expansion
Mixed lesion well demarcated No mutation
17 37 male right maxilla right facial swelling
pain and fever
Mixed lesion well demarcated No mutation
18 43 female right maxilla buccal bone expansion Mixed lesion well demarcated No mutation
19 47 male right maxilla bone swelling
nasal obstruction
Mixed lesion ill demarcated No mutation
20 6 male right maxilla bone swelling Mixed lesion well demarcated No mutation
21 9 male right mandible right facial swelling Radiolucent well demarcated No mutation
22 24 female anterior mandibular
region
pain Mixed lesion well demarcated No mutation
23 26 male left maxilla buccal bone expansion Mixed lesion well demarcated No mutation
24 10 male left maxilla left facial swelling Mixed lesion well demarcated No mutation
25 11 male right maxilla nasal obstruction Mixed lesion well demarcated No mutation
26 5 male left maxilla bone swelling Mixed lesion well demarcated No mutation
27 44 female right maxilla sense of numbness Mixed lesion ill demarcated No mutation
28 31 female left mandible bone swelling
looseness of teeth
Radiolucent well demarcated No mutation
29 17 male right maxilla bone swelling Mixed lesion ill demarcated No mutation
30 20 female right mandible bone swelling
occasional pain
Mixed lesion well demarcated No mutation
31 6 male left mandible bone swelling Radiolucent ill demarcated No mutation
32 11 female right mandible right facial swelling Mixed lesion well demarcated No mutation
33 14 male anterior mandibular
region
labial bone expansion Radiolucent ill demarcated No mutation
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somatic and located in exon 1. The mutation in case 1
was a frameshift mutation (c.13_16delCTTA), which
leads to a premature stop codon at position 15. The
frameshift mutation also causes the substitution of
the fifth amino acid, leucine, which was the first af-
fected amino acid, with an alanine (p.Leu5Alafs*15).
The novel mutation found in case 2, c.8_10delAC-
GinsCT, was a frameshift mutation that leads to a
premature stop codon at position 18. This mutation
causes the substitution of the third amino acid, aspar-
tic acid, with an alanine (p.Asp3Alafs*18) (Fig. 1).
Immunohistochemical detection of parafibromin expression
Using immunohistochemical analysis, we found that all
cases of sporadic OF showed strong parafibromin
expression in the nucleus, and that some showed parafi-
bromin expression in the cytoplasm of the spindle-
shaped lesion cells, including those cells that were
carriers of a CDC73 mutation (Fig. 2).
Discussion
Parafibromin, the product of CDC73, is believed to be im-
portant for embryonic development and tumorigenesis
Table 1 Clinical data and CDC73 mutation of 40 patients with sporadic ossifying fibromas (Continued)
34 20 female left maxilla bone swelling Radio-opaque well demarcated No mutation
35 21 female right mandible bone swelling Radiolucent ill demarcated No mutation
36 7 male right mandible bone swelling
numbness of lower lip
Mixed lesion ill demarcated No mutation
37 8 male left maxilla left facial swelling Mixed lesion ill demarcated No mutation
38 27 female left mandible bone swelling Mixed lesion well demarcated No mutation
39 19 female Les.1:right maxilla hard bone swelling Radiolucent well demarcated No mutation
Les.2:bilateral mandible




Fig. 1 Two novel somatic mutations of CDC73 identified in sporadic ossifying fibromas. Sequences of both peripheral blood (upper) showing the
wild-type sequence and tumor (medium: directly sequencing. Lower: clone sequencing) are shown. a In case 1, c.13_16delCTTA (highlighted in
small box), which leads to a frame shifting change with the fifth amino acid residue leucine as the first affected amino acid, changing into a
alanine. b The other novel mutation, c.8_10delACGinsCT (highlighted in small box), was found in case 2. The frame shifted from the third amino
acid residue aspartic acid that is changed into alanine
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[15]. Homozygous CDC73 knockout mutations in mice
led to in utero death by stage E6.5. Conditional knockout
of both CDC73 alleles in E8.5 or older mice resulted in
the retardation of embryonic growth and increased apop-
tosis, whereas in adult mice it resulted in cachexia and
death within 20 days [22]. Parafibromin is a ubiquitously
expressed nuclear protein [21]. In humans, parafibromin
interacts with RNA polymerase II via the human PAF1
complex, which also includes human Paf1, CTR9, and
Leo1. This complex regulates a number of key transcrip-
tional events, including transcription initiation, transcript
elongation, and post-transcriptional events, including
mRNA maturation and maintenance of poly (A) tail
length [16, 17].
Mutations in CDC73 have been frequently detected in
patients with HPT-JT and also occur in 20–29 % of indi-
viduals with apparently sporadic parathyroid carcinoma
[23]. However, the frequency of CDC73 mutations in
sporadic parathyroid adenomas is low, at 0–4 %, indicat-
ing that CDC73 mutations likely confer an aggressive
growth potential and may result in malignant transform-
ation of parathyroid cells [24]. CDC73 mutations have
been detected in between 0 and 33 % of individuals with
familial isolated primary hyperparathyroidism [23]. Som-
atic CDC73 mutations have also been found in sporadic
renal tumors [25].
The frequency of CDC73 mutations in individuals with
sporadic OF of the jaws has not been extensively studied.
In the present study, two somatic mutations were identified
in 40 cases of OF (5 %). This result suggested a possible
pathogenetic role for CDC73 in some cases of sporadic
OFs. Previously, a few cases of sporadic OF was found to
harbor a mutation in CDC73 [18, 26]. Further studies are
needed to clarified the exact frequency of CDC73 mutation
in sporadic OF due to limitation of sample size.
The CDC73 mutations identified in this study included
two novel somatic mutations (c.13_16delCTTA and
c.8_10delACGinsCT), which caused frameshifts and pre-
mature truncations of the protein. This finding is con-
sistent with previous studies showing that over 75 % of
the reported CDC73 mutations are frameshift or non-
sense mutations that are predicted to result in either
the truncation of the parafibromin protein or in loss
of the translated protein through nonsense-mediated
mRNA decay.
Somatic mutations of CDC73 were predominantly lo-
cated in exons 1 and 2 (55 and 21 %, respectively), in
contrast to germline mutations (22 and 16 %, respect-
ively) mainly detected in HPT-JT, which were predomin-
antly located in exon 7 (30 %). Only one somatic
mutation has been detected in exon 7 to date [24]. The
two mutations that we identified in OF both occurred in
exon 1, and a previous study on OF [18] also identified a
somatic mutation in exon 1. The basis of the differences
in the distribution of the germline and somatic CDC73
mutations remains to be elucidated.
In vitro studies have shown that parafibromin acts as a
tumor suppressor. Overexpression of parafibromin in-
hibits the proliferation of NIH3T3 and HEK293 cells,
increases G1 arrest and apoptosis in HeLa cells, and
downregulates expression of the cell cycle regulator,
cyclin D1 [27–29]. Likewise, RNAi-mediated inhib-
ition of parafibromin expression in HeLa cells re-
sulted in increased S-phase entry with reduction in
basal apoptosis and increase in expression of the
proto-oncogene, c-myc [30, 31].
According to Knudson’s two-hit model for tumor sup-
pressor genes [32] two mutations, one occurring in each
of the two alleles of a gene, or one mutation in one allele
of a tumor suppressor gene accompanied by the allelic
Fig. 2 Parafibromin staining by immunohistochemistry. All tumors, without (a) or with (b) CDC73 mutation (*200), showed strong nuclear and
cytoplasmic staining in both fibroblasts and osteoblasts within the lesion
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loss of the remaining wild-type allele, are required to
trigger neoplasm formation. Biallelic inactivation in
CDC73 has been detected in tumors in HPT-JT kindred
and in sporadic parathyroid carcinomas and renal
carcinomas [15]. Since parafibromin is ubiquitously
expressed, biallelic inactivation of CDC73 can be
detected immunohistochemically by the diffuse loss of
nuclear expression. This is a common feature in parathy-
roid carcinoma [33, 34].
However, the two-hit model may not apply to sporadic
OF. First, only one mutation was detected in each case,
even in the case with two somatic mutations reported by
Pimenta [18]. Second, normal parafibromin expression
was detected by immunohistochemistry. The effect of
mutated CDC73 on sporadic OFs needs to be studied
further.
Conclusions
Although CDC73 mutations are rare in sporadic OFs of
the jaws, CDC73 may play a role in the pathogenesis of
a small subset of tumors.
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